Parnax Lab Limited

PARNAXLAB6

INE383L01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:58 27/06/2024 BST			5-day change	1st Jan Change
103.5 ^INR	-1.90%		-7.64%	+17.40%

05-30	Parnax Lab Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
05-30	Parnax Lab Limited Approves Reconstitution of Committees of Board of Directors	CI

Parnax Lab Limited Announces Demise of Non-Executive Independent Director Manharbhai Navalchand Jhavari

March 01, 2021 at 07:19 am

Parnax Lab Limited announced demise of Non-Executive Independent Director Manharbhai Navalchand Jhavari on February 27, 2021.

Latest news about Parnax Lab Limited

Parnax Lab Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-30	CI
Parnax Lab Limited Approves Reconstitution of Committees of Board of Directors	05-30	CI
Parnax Lab Limited Announces Retirement of Vinayak Desai as an Independent Director	03-31	CI
Parnax Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Parnax Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Parnax Lab Limited Appoints Harish S. Panpalia as a Non-Executive Independent Director	29/09/23	CI
Parnax Lab Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/08/23	CI
Parnax Lab Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/05/23	CI
Parnax Lab Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	30/05/23	CI
Parnax Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Parnax Lab Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/08/22	CI
Parnax Lab Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/05/22	CI
Parnax Lab Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/05/22	CI
Parnax Lab Board Allots Over 2 Million Convertible Warrants to Promoters	24/03/22	MT
Parnax Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Parnax Lab Limited announced that it expects to receive INR 45.78375 million in funding	31/12/21	CI
Parnax Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	13/11/21	CI
Parnax Lab Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	14/08/21	CI
Parnax Lab Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/06/21	CI
Parnax Lab Limited Approves the Appointment of Preet Vijay Kukreja as Company Secretary and Compliance Officer	21/06/21	CI
Parnax Lab Limited Announces Resignation of Namrata Kambli as Company Secretary and Compliance Officer of the Company	31/05/21	CI
Parnax Lab Limited Announces Demise of Non-Executive Independent Director Manharbhai Navalchand Jhavari	01/03/21	CI
Parnax Lab Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	13/02/21	CI
Parnax Lab Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	12/11/20	CI
Parnax Lab Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	31/07/20	CI

Parnax Lab Limited is an India-based holding company. The Company is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations. It is also focused on the trading of pharmaceuticals and medicinal products. The Company operates through dealing in the pharmaceutical formulations segment. It is engaged in developing and delivering huge volumes of oral formulations, such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, special formulations for geriatrics, highly viscous products, suspensions and others. The Companyâs subsidiary is Naxpar Pharma Private Limited.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
PARNAX LAB LIMITED	+17.40%	14.5M
CSL LIMITED	+2.97%	94.74B
SAMSUNG BIOLOGICS CO.,LTD.	-3.68%	37.28B
BIOGEN INC.	-12.22%	32.68B
UCB	+74.21%	27.72B
BIOMARIN PHARMACEUTICAL INC.	-14.28%	16.19B
INCYTE CORPORATION	-2.41%	13.88B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.21%	11.58B
ALTEOGEN INC.	+188.83%	10.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-53.94%	9.54B